Congressional Testimony 2017

This section includes testimony by FDA officials before House and Senate Committees and Subcommittees.

June 2017

06/20/2017 President's Fiscal Year 2018 Budget Request (Senate)
Scott Gottlieb, M.D., before the Senate Committee on Appropriations, Subcommittee on Agriculture, Rural Development, Food and Drug Administration, and Related Agencies

05/25/2017 The President's FY2018 Budget Request for FDA
Scott Gottlieb, M.D., before the House Subcommittee on Agriculture, Rural Development, Food and Drug Administration, and Related Agencies
05/23/2017 U.S. Public Health Response to the Zika Virus: Continuing Challenges
Luciana Borio, M.D., before the House Committee on Energy and Commerce, Subcommittee on Oversight and Investigations
05/02/2017 Examining Improvements to the Regulation of Medical Technologies
Jeffrey Shuren, M.D., J.D., before the House Committee on Energy and Commerce, Subcommittee on Health

03/28/2017 Examining FDA’s Medical Device User Fee Program
Jeffrey Shuren, M.D., J.D. before the Committee on Energy and Commerce Subcommittee on Health, United States House of Representatives
03/21/2017 Prescription Drug User Fee Act Reauthorization (PDUFA VI), Medical Device User Fee Act Reauthorization (MDUFA IV), Generic Drug User Fee Act Reauthorization (GDUFA II), and Biosimilar User Fee Act Reauthorization (BsUFA II)
Janet Woodcock, M.D., Peter Marks, M.D., Ph.D., and Jeffrey Shuren, M.D., J.D., before the Committee on Health, Education, Labor and Pensions, U.S. Senate
03/02/2017 Generic Drug User Fee Act Reauthorization (GDUFA II), Biosimilar User Fee Act Reauthorization (BsUFA II)
Janet Woodcock, M.D. before the Committee on Energy and Commerce Subcommittee on Health, United States House of Representatives